Cargando...
Opportunities for model-based precision dosing in the treatment of sickle cell anemia
Hydroxyurea is the primary pharmacotherapy to prevent complications of sickle cell anemia (SCA). Accumulated clinical experience across multiple age ranges has suggested that the use of an individualized maximum tolerated dose (MTD) will achieve optimal benefit of hydroxyurea treatment. However, the...
Guardado en:
| Publicado en: | Blood Cells Mol Dis |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5677562/ https://ncbi.nlm.nih.gov/pubmed/28807656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcmd.2017.08.007 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|